Free Trial
NASDAQ:BCLI

Brainstorm Cell Therapeutics Q4 2023 Earnings Report

Brainstorm Cell Therapeutics logo
$0.98 +0.06 (+5.98%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.99 +0.02 (+1.54%)
As of 04/25/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics EPS Results

Actual EPS
-$1.65
Consensus EPS
-$2.25
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Brainstorm Cell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Brainstorm Cell Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
8:15AM ET

Upcoming Earnings

Brainstorm Cell Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Brainstorm Cell Therapeutics Earnings Headlines

Brainstorm Cell Therapeutics adjusts quorum requirement
Claim Your FREE Protection Guide
In the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code... And since then, "in the know" patriots have quietly used this same "Trump loophole" to shield their life savings from the economic chaos. But with Trump now forcefully bringing back millions of manufacturing jobs from Mexico, China, and the entire BRICS anti-dollar coalition...
See More Brainstorm Cell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Brainstorm Cell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainstorm Cell Therapeutics and other key companies, straight to your email.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics (NASDAQ:BCLI), a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

View Brainstorm Cell Therapeutics Profile

More Earnings Resources from MarketBeat